Phase I crossover study of DNA-protein kinase inhibitor peposertib in healthy volunteers: Effect of food and pharmacokinetics of an oral suspension

被引:2
|
作者
Becker, Andreas [1 ]
Krebs-Brown, Axel [1 ]
Vetter, Claudia [1 ]
Reuter, Tanja [1 ]
Rodriguez-Gutierrez, Almudena [2 ,3 ]
You, Xiaoli [4 ]
Lissy, Michael [5 ]
机构
[1] Healthcare Business Merck KGaA, Frankfurter Str 250,F135-003, D-64293 Darmstadt, Germany
[2] SLU, Merck, Madrid, Spain
[3] Merck KGaA, Darmstadt, Germany
[4] EMD Serono, Billerica, MA USA
[5] NUVISAN GmbH, Neu Ulm, Germany
来源
关键词
CRYO-EM STRUCTURE; PK; ATM;
D O I
10.1111/cts.13657
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Peposertib is an orally administered inhibitor of DNA-dependent protein kinase. We evaluated the effect of food on its pharmacokinetics, and examined the pharmacokinetics of an oral suspension (OS) of disintegrated tablets, in a phase I, open-label, crossover three-period study (NCT04702698). Twelve healthy volunteers were randomized to one of six treatment sequences. They received a single dose of peposertib 100 mg as film-coated tablets under fasted or fed conditions ("tablet fasted" or "tablet fed") or as an OS under fasted conditions ("OS fasted"), with washout between treatments. Using healthy volunteers was possible because, despite its mechanism of action being suppression of DNA repair, peposertib has shown no genotoxic effect in animals. A mild food effect was observed with peposertib tablets. Fed-to-fasted ratios were: area under the curve from time 0 to time t (AUC(0-t)), 123.81% (90% confidence interval [CI]: 108.04, 141.87%); AUC from zero to infinity (AUC(0-infinity)), 110.28% (90% CI 100.71, 120.77%); and maximum concentration (C-max) 104.47% (90% CI: 79.15, 137.90%). C-max was delayed under fed conditions (median time to maximum concentration [T-max] was 3.5 h [tablet fed] vs. 1 h [tablet fasted]). OS-to-tablet (fasted) ratios were: AUC(0-t), 124.83% (90% CI: 111.50%, 139.76%); AUC(0-infinity), 119.05% (90% CI: 104.47, 135.67%); and C-max 173.29% (90% CI: 135.78, 221.16%). Median T-max was 0.5 h (OS fasted) versus 1 h (tablet). All treatments were well-tolerated in healthy volunteers. Peposertib tablets can be taken with or without food; if combined with chemotherapy or radiotherapy, the delay in C-max must be considered to optimize the chemo- or radiosensitizing effect. The peposertib OS form represents an alternative route of administration in patients with specific cancers causing dysphagia. However, the OS form should be part of future dose optimization strategies in relevant settings.
引用
收藏
页码:2628 / 2639
页数:12
相关论文
共 50 条
  • [41] Effect of food on the pharmacokinetics of dronabinol oral solution versus dronabinol capsules in healthy volunteers.
    Smith, Christina Cognata
    Oh, D. Alexander
    Parikh, Neha
    Khurana, Varun
    Vetticaden, Santosh
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (26)
  • [42] Effect of food on the pharmacokinetics of dronabinol oral solution versus dronabinol capsules in healthy volunteers.
    Oh, D. Alexander
    Parikh, Neha
    Khurana, Varun
    Smith, Christina Cognata
    Vetticaden, Santosh
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] PHARMACOKINETIC PROFILE OF MGCD265, AN ORAL TYROSINE KINASE INHIBITOR, WITH OR WITHOUT FOOD IN HEALTHY VOLUNTEERS
    Sicard, E.
    Juretic, M.
    Drouin, M.
    Reid, G.
    Wang, J.
    Hunt, W.
    Maroun, C.
    Besterman, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 169 - 169
  • [44] The effect of food and formulation on the population pharmacokinetics of cholesteryl ester transferase protein inhibitor DRL-17822 in healthy male volunteers
    Goulooze, Sebastiaan C.
    Kruithof, Annelieke C.
    Alikunju, Shanavas
    Gautam, Anirudh
    Burggraaf, Jacobus
    Kamerling, Ingrid M. C.
    Stevens, Jasper
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (10) : 2095 - 2101
  • [45] A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [14C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers
    Sufeng Zhou
    Feng Shao
    Zhaoqiang Xu
    Lu Wang
    Ke Jin
    Lijun Xie
    Juan Chen
    Yun Liu
    Hongwen Zhang
    Ning Ou
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 563 - 573
  • [46] A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [14C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers
    Zhou, Sufeng
    Shao, Feng
    Xu, Zhaoqiang
    Wang, Lu
    Jin, Ke
    Xie, Lijun
    Chen, Juan
    Liu, Yun
    Zhang, Hongwen
    Ou, Ning
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (03) : 563 - 573
  • [47] Effects of Oral Posaconazole on the Pharmacokinetic Properties of Oral and Intravenous Midazolam: A Phase I, Randomized, Open-Label, Crossover Study in Healthy Volunteers
    Krishna, Gopal
    Moton, Allen
    Ma, Lei
    Savant, Ishani
    Martinho, Monika
    Seiberling, Michael
    McLeod, James
    CLINICAL THERAPEUTICS, 2009, 31 (02) : 286 - 298
  • [48] SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND FOOD EFFECT OF AN ORAL BRUTON'S TYROSINE KINASE INHIBITOR HM71224 IN HEALTHY SUBJECTS
    Yoon, Y. -K.
    Hadi, S.
    Iersel, T. V.
    Sin, H. J.
    Lee, K. O.
    Lee, J.
    Song, J. Y.
    Jang, S.
    Lee, Y. -M.
    Kang, J.
    Suh, K. H.
    Son, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 231 - 231
  • [49] Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers
    Huang, H. -L. A.
    Vaidyanathan, S.
    Yeh, C. -M.
    BiZot, M. -N.
    Dieterich, H. A.
    Dole, W. P.
    Howard, D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (09) : 2449 - 2456
  • [50] The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants
    Patel, Maulik
    Chen, Joseph
    McGrory, Stephanie
    O'Gorman, Melissa
    Nepal, Sunil
    Ginman, Katherine
    Pithavala, Yazdi K.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (01) : 131 - 139